TIE-2 expressing monocytes in human cancers

References

• Du R, Lu KV, Petritsch C, Liu P, Ganss R, Passegue E, Song H, Vandenberg S, Johnson RS, Werb Z et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008; 13:206-20; PMID:18328425; http://dx.doi.org/10.1016/j.ccr.2008.01.034
   PubMed Web of Science ®Google Scholar
• Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA, Qian H, Xue XN, Pollard JW. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 2006; 66:11238-46; PMID:17114237; http://dx.doi.org/10.1158/0008-5472.CAN-06-1278
   PubMed Web of Science ®Google Scholar
• Lin P, Polverini P, Dewhirst M, Shan S, Rao PS, Peters K. Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth. J Clin Invest 1997; 100:2072-8; PMID:9329972; http://dx.doi.org/10.1172/JCI119740
   PubMed Web of Science ®Google Scholar
• Harney AS, Arwert EN, Entenberg D, Wang Y, Guo P, Qian BZ, Oktay MH, Pollard JW, Jones JG, Condeelis JS. Real-time imaging reveals local, transient vascular permeability, and tumor cell intravasation stimulated by TIE2hi macrophage-derived VEGFA. Cancer Discov 2015; 5:932-43; PMID:26269515; http://dx.doi.org/10.1158/2159-8290.CD-15-0012
   PubMed Web of Science ®Google Scholar
• Smith HA, Kang Y. The metastasis-promoting roles of tumor-associated immune cells. J Mol Med 2013; 91:411-29; PMID:23515621; http://dx.doi.org/10.1007/s00109-013-1021-5
   PubMed Web of Science ®Google Scholar
• Costa NL, Valadares MC, Souza PP, Mendonca EF, Oliveira JC, Silva TA, Batista AC. Tumor-associated macrophages and the profile of inflammatory cytokines in oral squamous cell carcinoma. Oral Oncol 2013; 49:216-23; PMID:23089461; http://dx.doi.org/10.1016/j.oraloncology.2012.09.012
   PubMed Web of Science ®Google Scholar
• Han Q, Shi H, Liu F. CD163(+) M2-type tumor-associated macrophage support the suppression of tumor-infiltrating T cells in osteosarcoma. Int Immunopharmacol 2016; 34:101-6; PMID:26938675; http://dx.doi.org/10.1016/j.intimp.2016.01.023
   PubMed Web of Science ®Google Scholar
• Wang R, Zhang J, Chen S, Lu M, Luo X, Yao S, Liu S, Qin Y, Chen H. Tumor-associated macrophages provide a suitable microenvironment for non-small lung cancer invasion and progression. Lung Cancer 2011; 74:188-96; PMID:21601305; http://dx.doi.org/10.1016/j.lungcan.2011.04.009
   PubMed Web of Science ®Google Scholar
• Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, Rey-Giraud F, Pradel LP, Feuerhake F, Klaman I et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell 2014; 25:846-59; PMID:24898549; http://dx.doi.org/10.1016/j.ccr.2014.05.016
   PubMed Web of Science ®Google Scholar
• Tap WD, Wainberg ZA, Anthony SP, Ibrahim PN, Zhang C, Healey JH, Chmielowski B, Staddon AP, Cohn AL, Shapiro GI et al. Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. N Eng J Med 2015; 373:428-37; PMID:26222558; http://dx.doi.org/10.1056/NEJMoa1411366
   PubMed Web of Science ®Google Scholar
• De Palma M, Venneri MA, Galli R, Sergi L, Politi LS, Sampaolesi M, Naldini L. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005; 8:211-26; PMID:16169466; http://dx.doi.org/10.1016/j.ccr.2005.08.002
   PubMed Web of Science ®Google Scholar
• Pucci F, Venneri MA, Biziato D, Nonis A, Moi D, Sica A, Di Serio C, Naldini L, De Palma M. A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood “resident” monocytes, and embryonic macrophages suggests common functions and developmental relationships. Blood 2009; 114:901-14; PMID:19383967; http://dx.doi.org/10.1182/blood-2009-01-200931
   PubMed Web of Science ®Google Scholar
• Coffelt SB, Tal AO, Scholz A, De Palma M, Patel S, Urbich C, Biswas SK, Murdoch C, Plate KH, Reiss Y et al. Angiopoietin-2 regulates gene expression in TIE2-expressing monocytes and augments their inherent proangiogenic functions. Cancer Res 2010; 70:5270-80; PMID:20530679; http://dx.doi.org/10.1158/0008-5472.CAN-10-0012
   PubMed Web of Science ®Google Scholar
• Asahara T, Chen D, Takahashi T, Fujikawa K, Kearney M, Magner M, Yancopoulos GD, Isner JM. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res 1998; 83:233-40; PMID:9710115; http://dx.doi.org/10.1161/01.RES.83.3.233
   PubMed Web of Science ®Google Scholar
• Venneri MA, De Palma M, Ponzoni M, Pucci F, Scielzo C, Zonari E, Mazzieri R, Doglioni C, Naldini L. Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood 2007; 109:5276-85; PMID:17327411; http://dx.doi.org/10.1182/blood-2006-10-053504
   PubMed Web of Science ®Google Scholar
• Guex N, Crespo I, Bron S, Ifticene-Treboux A, Faes-Van't Hull E, Kharoubi S, Liechti R, Werffeli P, Ibberson M, Majo F et al. Angiogenic activity of breast cancer patients' monocytes reverted by combined use of systems modeling and experimental approaches. PLoS Comput Biol 2015; 11:e1004050; PMID:25768678; http://dx.doi.org/10.1371/journal.pcbi.1004050
   PubMedGoogle Scholar
• Bron S, Henry L, Faes-Van't Hull E, Turrini R, Vanhecke D, Guex N, Ifticene-Treboux A, Marina Iancu E, Semilietof A, Rufer N et al. TIE-2-expressing monocytes are lymphangiogenic and associate specifically with lymphatics of human breast cancer. Oncoimmunology 2016; 5:e1073882; PMID:27057438; http://dx.doi.org/10.1080/2162402X.2015.1073882
   PubMed Web of Science ®Google Scholar
• Ibberson M, Bron S, Guex N, Faes-van't Hull E, Ifticene-Treboux A, Henry L, Lehr HA, Delaloye JF, Coukos G, Xenarios I et al. TIE-2 and VEGFR kinase activities drive immunosuppressive function of TIE-2-expressing monocytes in human breast tumors. Clin Cancer Res 2013; 19:3439-49; PMID:23649001; http://dx.doi.org/10.1158/1078-0432.CCR-12-3181
   PubMed Web of Science ®Google Scholar
• Vesosky B, Hurwitz AA. Modulation of costimulation to enhance tumor immunity. Cancer Immunol Immunother 2003; 52:663-9; PMID:12920481; http://dx.doi.org/10.1007/s00262-003-0424-5
   PubMed Web of Science ®Google Scholar
• Facciabene A, Motz GT, Coukos G. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res 2012; 72:2162-71; PMID:22549946; http://dx.doi.org/10.1158/0008-5472.CAN-11-3687
   PubMed Web of Science ®Google Scholar
• Robinson BD, Sica GL, Liu YF, Rohan TE, Gertler FB, Condeelis JS, Jones JG. Tumor microenvironment of metastasis in human breast carcinoma: a potential prognostic marker linked to hematogenous dissemination. Clin Cancer Res 2009; 15:2433-41; PMID:19318480; http://dx.doi.org/10.1158/1078-0432.CCR-08-2179
   PubMed Web of Science ®Google Scholar
• Rohan TE, Xue X, Lin HM, D'Alfonso TM, Ginter PS, Oktay MH et al. Tumor microenvironment of metastasis and risk of distant metastasis of breast cancer. J Natl Cancer Inst 2014; 106; PMID:24895374; http://dx.doi.org/10.1093/jnci/dju136
   PubMedGoogle Scholar
• Wong KL, Yeap WH, Tai JJ, Ong SM, Dang TM, Wong SC. The three human monocyte subsets: implications for health and disease. Immunol Res 2012; 53:41-57; PMID:22430559; http://dx.doi.org/10.1007/s12026-012-8297-3
   PubMed Web of Science ®Google Scholar
• Zawada AM, Rogacev KS, Rotter B, Winter P, Marell RR, Fliser D, Heine GH. SuperSAGE evidence for CD14++CD16+ monocytes as a third monocyte subset. Blood 2011; 118:e50-61; PMID:21803849; http://dx.doi.org/10.1182/blood-2011-01-326827
   PubMed Web of Science ®Google Scholar
• MacDonald KP, Palmer JS, Cronau S, Seppanen E, Olver S, Raffelt NC, Kuns R, Pettit AR, Clouston A, Wainwright B et al. An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation. Blood 2010; 116:3955-63; PMID:20682855; http://dx.doi.org/10.1182/blood-2010-02-266296
   PubMed Web of Science ®Google Scholar
• Movahedi K, Laoui D, Gysemans C, Baeten M, Stange G, Van den Bossche J, Mack M, Pipeleers D, In't Veld P, De Baetselier P et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res 2010; 70:5728-39; PMID:20570887; http://dx.doi.org/10.1158/0008-5472.CAN-09-4672
   PubMed Web of Science ®Google Scholar
• Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275:964-7; PMID:9020076; http://dx.doi.org/10.1126/science.275.5302.964
   PubMed Web of Science ®Google Scholar
• Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig B, Marks W, Witte L et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001; 7:1194-201; PMID:11689883; http://dx.doi.org/10.1038/nm1101-1194
   PubMed Web of Science ®Google Scholar
• Salven P, Mustjoki S, Alitalo R, Alitalo K, Rafii S. VEGFR-3 and CD133 identify a population of CD34+ lymphatic/vascular endothelial precursor cells. Blood 2003; 101:168-72; PMID:12393704; http://dx.doi.org/10.1182/blood-2002-03-0755
   PubMed Web of Science ®Google Scholar
• Dome B, Hendrix MJ, Paku S, Tovari J, Timar J. Alternative vascularization mechanisms in cancer: pathology and therapeutic implications. Am J Pathol 2007; 170:1-15; PMID:17200177; http://dx.doi.org/10.2353/ajpath.2007.060302
   PubMed Web of Science ®Google Scholar
• Resch T, Pircher A, Kahler CM, Pratschke J, Hilbe W. Endothelial progenitor cells: current issues on characterization and challenging clinical applications. Stem Cell Rev 2012; 8:926-39; PMID:22095429; http://dx.doi.org/10.1007/s12015-011-9332-9
   PubMed Web of Science ®Google Scholar
• Sussman LK, Upalakalin JN, Roberts MJ, Kocher O, Benjamin LE. Blood markers for vasculogenesis increase with tumor progression in patients with breast carcinoma. Cancer Biol Ther 2003; 2:255-6; http://dx.doi.org/10.4161/cbt.2.3.363
   PubMed Web of Science ®Google Scholar
• Hilbe W, Dirnhofer S, Oberwasserlechner F, Schmid T, Gunsilius E, Hilbe G, Wöll E, Kähler CM. CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer. J Clin Pathol 2004; 57:965-9; PMID:15333659; http://dx.doi.org/10.1136/jcp.2004.016444
   PubMed Web of Science ®Google Scholar
• Pirro M, Cagini L, Mannarino MR, Andolfi M, Potenza R, Paciullo F, Bianconi V, Frangione MR, Bagaglia F, Puma F et al. Reduced survival in patients with early-stage non-small-cell lung cancer is associated with high pleural endothelial progenitor cell levels. Eur J Cardiothorac Surg 2016; 50:1053-9; PMID:27301385; http://dx.doi.org/10.1093/ejcts/ezw197
   PubMed Web of Science ®Google Scholar
• Arbab AS, Janic B, Knight RA, Anderson SA, Pawelczyk E, Rad AM, Read EJ, Pandit SD, Frank JA. Detection of migration of locally implanted AC133+ stem cells by cellular magnetic resonance imaging with histological findings. FASEB J 2008; 22:3234-46; PMID:18556461; http://dx.doi.org/10.1096/fj.07-105676
   PubMed Web of Science ®Google Scholar
• Peters BA, Diaz LA, Polyak K, Meszler L, Romans K, Guinan EC, Antin JH, Myerson D, Hamilton SR, Vogelstein B et al. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med 2005; 11:261-2; PMID:15723071; http://dx.doi.org/10.1038/nm1200
   PubMed Web of Science ®Google Scholar
• Dome B, Timar J, Dobos J, Meszaros L, Raso E, Paku S, Kenessey I, Ostoros G, Magyar M, Ladanyi A et al. Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer. Cancer Res 2006; 66:7341-7; PMID:16849585; http://dx.doi.org/10.1158/0008-5472.CAN-05-4654
   PubMed Web of Science ®Google Scholar
• Zhang H, Vakil V, Braunstein M, Smith EL, Maroney J, Chen L, Dai K, Berenson JR, Hussain MM, Klueppelberg U et al. Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood 2005; 105:3286-94; PMID:15618473; http://dx.doi.org/10.1182/blood-2004-06-2101
   PubMed Web of Science ®Google Scholar
• Van't Hull EF, Bron S, Henry L, Ifticene-Treboux A, Turrini R, Coukos G, Delaloye JF, Doucey MA. Bone marrow-derived cells are implicated as a source of lymphatic endothelial progenitors in human breast cancer. Oncoimmunology 2014; 3:e29080; PMID:25101222; http://dx.doi.org/10.4161/onci.29080
   PubMedGoogle Scholar
• De Palma M, Murdoch C, Venneri MA, Naldini L, Lewis CE. Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications. Trends Immunol 2007; 28:519-24; PMID:17981504; http://dx.doi.org/10.1016/j.it.2007.09.004
   PubMed Web of Science ®Google Scholar
• Cattin S, Fellay B, Pradervand S, Trojan A, Ruhstaller T, Ruegg C, Fürstenberger G. Bevacizumab specifically decreases elevated levels of circulating KIT+CD11b+ cells and IL-10 in metastatic breast cancer patients. Oncotarget 2016; 7:11137-50; PMID:26840567
   PubMed Web of Science ®Google Scholar
• Doucey MA, Xenarios I. Toward a rational design of combination therapy in cancer. Oncoimmunology 2015; 4:e1046674; PMID:26451320; http://dx.doi.org/10.1080/2162402X.2015.1046674
   PubMedGoogle Scholar
• Forget MA, Voorhees JL, Cole SL, Dakhlallah D, Patterson IL, Gross AC, Moldovan L, Mo X, Evans R, Marsh CB et al. Macrophage colony-stimulating factor augments Tie2-expressing monocyte differentiation, angiogenic function, and recruitment in a mouse model of breast cancer. PLoS One 2014; 9:e98623; PMID:24892425; http://dx.doi.org/10.1371/journal.pone.0098623
   PubMed Web of Science ®Google Scholar
• Tsutsui S, Inoue H, Yasuda K, Suzuki K, Takeuchi H, Nishizaki T, Higashi H, Era S, Mori M. Angiopoietin 2 expression in invasive ductal carcinoma of the breast: its relationship to the VEGF expression and microvessel density. Breast Cancer Res Treat 2006; 98:261-6; PMID:16538528; http://dx.doi.org/10.1007/s10549-005-9157-9
   PubMed Web of Science ®Google Scholar
• Ji J, Zhang G, Sun B, Yuan H, Huang Y, Zhang J, Wei X, Zhang X, Hou J. The frequency of tumor-infiltrating Tie-2-expressing monocytes in renal cell carcinoma: its relationship to angiogenesis and progression. Urology 2013; 82:974.e9-13; PMID:23769120; http://dx.doi.org/10.1016/j.urology.2013.05.026
   PubMed Web of Science ®Google Scholar
• De Palma M, Coukos G, Semela D. TIE2-expressing monocytes: a novel cellular biomarker for hepatocellular carcinoma? Hepatology 2013; 57:1294-6; PMID:22911438; http://dx.doi.org/10.1002/hep.26025
   PubMed Web of Science ®Google Scholar
• Matsubara T, Kanto T, Kuroda S, Yoshio S, Higashitani K, Kakita N, Miyazaki M, Sakakibara M, Hiramatsu N, Kasahara A et al. TIE2-expressing monocytes as a diagnostic marker for hepatocellular carcinoma correlates with angiogenesis. Hepatology 2013; 57:1416-25; PMID:22815256; http://dx.doi.org/10.1002/hep.25965
   PubMed Web of Science ®Google Scholar
• Atanasov G, Hau HM, Dietel C, Benzing C, Krenzien F, Brandl A, Englisch JP, Wiltberger G, Schierle K, Robson SC et al. Prognostic significance of TIE2-expressing monocytes in hilar cholangiocarcinoma. J Surg Oncol 2016; 114:91-8; PMID:27111031; http://dx.doi.org/10.1002/jso.24249
   PubMed Web of Science ®Google Scholar
• Goede V, Coutelle O, Shimabukuro-Vornhagen A, Holtick U, Neuneier J, Koslowsky TC, Weihrauch MR, von Bergwelt-Baildon M, Hacker UT. Analysis of Tie2-expressing monocytes (TEM) in patients with colorectal cancer. Cancer Invest 2012; 30:225-30; PMID:22171993; http://dx.doi.org/10.3109/07357907.2011.636114
   PubMed Web of Science ®Google Scholar
• Schauer D, Starlinger P, Reiter C, Jahn N, Zajc P, Buchberger E, Bachleitner-Hofmann T, Bergmann M, Stift A, Gruenberger T et al. Intermediate monocytes but not TIE2-expressing monocytes are a sensitive diagnostic indicator for colorectal cancer. PLoS One 2012; 7:e44450; PMID:22973451; http://dx.doi.org/10.1371/journal.pone.0044450
   PubMedGoogle Scholar
• Schauer D, Starlinger P, Alidzanovic L, Zajc P, Maier T, Feldman A, Padickakudy R, Buchberger E, Elleder V, Spittler A et al. Chemotherapy of colorectal liver metastases induces a rapid rise in intermediate blood monocytes which predicts treatment response. Oncoimmunology 2016; 5:e1160185; PMID:27471631; http://dx.doi.org/10.1080/2162402X.2016.1160185
   PubMedGoogle Scholar
• Gabrusiewicz K, Liu D, Cortes-Santiago N, Hossain MB, Conrad CA, Aldape KD, Fuller GN, Marini FC, Alonso MM, Idoate MA et al. Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes. Oncotarget 2014; 5:2208-20; PMID:24809734; http://dx.doi.org/10.18632/oncotarget.1893
   PubMed Web of Science ®Google Scholar
• Cortes-Santiago N, Hossain MB, Gabrusiewicz K, Fan X, Gumin J, Marini FC, Alonso MM, Lang F, Yung WK, Fueyo J et al. Soluble Tie2 overrides the heightened invasion induced by anti-angiogenesis therapies in gliomas. Oncotarget 2016; 7:16146-57; PMID:26910374
   PubMed Web of Science ®Google Scholar
• Figueroa-Vega N, Diaz A, Adrados M, Alvarez-Escola C, Paniagua A, Aragones J, Martín-Pérez E, Leskela S, Moreno-Otero R, González-Amaro R et al. The association of the angiopoietin/Tie-2 system with the development of metastasis and leukocyte migration in neuroendocrine tumors. Endocr Relat Cancer 2010; 17:897-908; PMID:20696814; http://dx.doi.org/10.1677/ERC-10-0020
   PubMed Web of Science ®Google Scholar
• Pulaski HL, Spahlinger G, Silva IA, McLean K, Kueck AS, Reynolds RK, Coukos G, Conejo-Garcia JR, Buckanovich RJ. Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer. J Transl Med 2009; 7:49; PMID:19545375; http://dx.doi.org/10.1186/1479-5876-7-49
   PubMed Web of Science ®Google Scholar
• Riccioni R, Calzolari A, Biffoni M, Senese M, Riti V, Petrucci E, Pasquini L, Cedrone M, Lo-Coco F, Diverio D et al. Podocalyxin is expressed in normal and leukemic monocytes. Blood Cells Mol Dis 2006; 37:218-25; PMID:17059890; http://dx.doi.org/10.1016/j.bcmd.2006.09.001
   PubMed Web of Science ®Google Scholar
• Riccioni R, Diverio D, Mariani G, Buffolino S, Riti V, Saulle E, Petrucci E, Cedrone M, Lo-Coco F, Foà R et al. Expression of Tie-2 and other receptors for endothelial growth factors in acute myeloid leukemias is associated with monocytic features of leukemic blasts. Stem Cells 2007; 25:1862-71; PMID:17446561; http://dx.doi.org/10.1634/stemcells.2006-0700
   PubMed Web of Science ®Google Scholar
• Maffei R, Bulgarelli J, Fiorcari S, Bertoncelli L, Martinelli S, Guarnotta C, Castelli I, Deaglio S, Debbia G, De Biasi S et al. The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation. Haematologica 2013; 98:1115-23; PMID:23349302; http://dx.doi.org/10.3324/haematol.2012.073080
   PubMed Web of Science ®Google Scholar
• Campanelli R, Rosti V, Fois G, Bonetti E, Barosi G, Massa M. CD14(bright)CD16(low) intermediate monocytes expressing Tie2 are increased in the peripheral blood of patients with primary myelofibrosis. Exp Hematol 2014; 42:244-6; PMID:24333662; http://dx.doi.org/10.1016/j.exphem.2013.12.002
   PubMed Web of Science ®Google Scholar
• Ran S, Montgomery KE. Macrophage-mediated lymphangiogenesis: the emerging role of macrophages as lymphatic endothelial progenitors. Cancers 2012; 4:618-57; PMID:22946011; http://dx.doi.org/10.3390/cancers4030618
   PubMedGoogle Scholar
• Alitalo A, Detmar M. Interaction of tumor cells and lymphatic vessels in cancer progression. Oncogene 2012; 31:4499-508; PMID:22179834; http://dx.doi.org/10.1038/onc.2011.602
   PubMed Web of Science ®Google Scholar
• Ran S, Volk L, Hall K, Flister MJ. Lymphangiogenesis and lymphatic metastasis in breast cancer. Pathophysiology 2010; 17:229-51; http://dx.doi.org/10.1016/j.pathophys.2009.11.003
   PubMedGoogle Scholar
• Schoppmann SF, Birner P, Stockl J, Kalt R, Ullrich R, Caucig C, Kriehuber E, Nagy K, Alitalo K, Kerjaschki D. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol 2002; 161:947-56; PMID:12213723; http://dx.doi.org/10.1016/S0002-9440(10)64255-1
   PubMed Web of Science ®Google Scholar
• Storr SJ, Safuan S, Mitra A, Elliott F, Walker C, Vasko MJ, Ho B, Cook M, Mohammed RA, Patel PM et al. Objective assessment of blood and lymphatic vessel invasion and association with macrophage infiltration in cutaneous melanoma. Mod Pathol 2012; 25:493-504; PMID:22080065; http://dx.doi.org/10.1038/modpathol.2011.182
   PubMed Web of Science ®Google Scholar
• Ding P, Wang W, Wang J, Yang Z, Xue L. Expression of tumor-associated macrophage in progression of human glioma. Cell Biochem Biophys 2014; 70:1625-31; PMID:25182001; http://dx.doi.org/10.1007/s12013-014-0105-3
   PubMed Web of Science ®Google Scholar
• Zhang W, Wang L, Zhou D, Cui Q, Zhao D, Wu Y. Expression of tumor-associated macrophages and vascular endothelial growth factor correlates with poor prognosis of peripheral T-cell lymphoma, not otherwise specified. Leuk Lymphoma 2011; 52:46-52; PMID:21077742; http://dx.doi.org/10.3109/10428194.2010.529204
   PubMed Web of Science ®Google Scholar
• Kurahara H, Shinchi H, Mataki Y, Maemura K, Noma H, Kubo F, Sakoda M, Ueno S, Natsugoe S, Takao S. Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J Surg Res 2011; 167:e211-9; PMID:19765725; http://dx.doi.org/10.1016/j.jss.2009.05.026
   PubMed Web of Science ®Google Scholar
• Adams DL, Martin SS, Alpaugh RK, Charpentier M, Tsai S, Bergan RC, Ogden IM, Catalona W, Chumsri S, Tang CM et al. Circulating giant macrophages as a potential biomarker of solid tumors. Proc Natl Acad Sci USA 2014; 111:3514-9; PMID:24550495; http://dx.doi.org/10.1073/pnas.1320198111
   PubMed Web of Science ®Google Scholar
• Kerjaschki D, Bago-Horvath Z, Rudas M, Sexl V, Schneckenleithner C, Wolbank S, Bartel G, Krieger S, Kalt R, Hantusch B et al. Lipoxygenase mediates invasion of intrametastatic lymphatic vessels and propagates lymph node metastasis of human mammary carcinoma xenografts in mouse. J Clin Invest 2011; 121:2000-12; PMID:21540548; http://dx.doi.org/10.1172/JCI44751
   PubMed Web of Science ®Google Scholar
• Van den Eynden GG, Vandenberghe MK, van Dam PJ, Colpaert CG, van Dam P, Dirix LY, Vermeulen PB, Van Marck EA. Increased sentinel lymph node lymphangiogenesis is associated with nonsentinel axillary lymph node involvement in breast cancer patients with a positive sentinel node. Clin Cancer Res 2007; 13:5391-7; PMID:17875768; http://dx.doi.org/10.1158/1078-0432.CCR-07-1230
   PubMed Web of Science ®Google Scholar
• Quail DF, Joyce JA. Molecular pathways: deciphering mechanisms of resistance to macrophage-targeted therapies. Clin Cancer Res 2016; 23(4):876-84; PMID:27895033; http://dx.doi.org/10.1158/1078-0432
   PubMed Web of Science ®Google Scholar
• Tang X, Mo C, Wang Y, Wei D, Xiao H. Anti-tumour strategies aiming to target tumour-associated macrophages. Immunology 2013; 138:93-104; PMID:23113570; http://dx.doi.org/10.1111/imm.12023
   PubMed Web of Science ®Google Scholar
• Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY et al. Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): long-term survival, impact of ascites, and progression-free survival-2. Gynecol Oncol 2016; 143:27-34; PMID:27546885; http://dx.doi.org/10.1016/j.ygyno.2016.07.112
   PubMed Web of Science ®Google Scholar
• Pfizer. PF-04856884 (CVX-060) in Combination with Axitinib in Patients with Previously Treated Metastatic Renal Cell Carcinoma. Bethesda, MD, USA: National Library of Medicine 2000–2016. Available from: https://clinicaltrialsgov/ct2/show/NCT01441414 2012
   Google Scholar
• Pili R, Carducci M, Brown P, Hurwitz H. An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer. Invest New Drugs 2014; 32:1258-68; PMID:25152243; http://dx.doi.org/10.1007/s10637-014-0147-9
   PubMed Web of Science ®Google Scholar
• De Palma M, Naldini L. Angiopoietin-2 TIEs up macrophages in tumor angiogenesis. Clin Cancer Res 2011; 17:5226-32; PMID:21576085; http://dx.doi.org/10.1158/1078-0432.CCR-10-0171
   PubMed Web of Science ®Google Scholar
• Priceman SJ, Sung JL, Shaposhnik Z, Burton JB, Torres-Collado AX, Moughon DL, Johnson M, Lusis AJ, Cohen DA, Iruela-Arispe ML et al. Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Blood 2010; 115:1461-71; PMID:20008303; http://dx.doi.org/10.1182/blood-2009-08-237412
   PubMed Web of Science ®Google Scholar
• Laurent J, Hull EF, Touvrey C, Kuonen F, Lan Q, Lorusso G, Doucey MA, Ciarloni L, Imaizumi N, Alghisi GC et al. Proangiogenic factor PlGF programs CD11b(+) myelomonocytes in breast cancer during differentiation of their hematopoietic progenitors. Cancer Res 2011; 71:3781-91; PMID:21507936; http://dx.doi.org/10.1158/0008-5472.CAN-10-3684
   PubMed Web of Science ®Google Scholar